Market Leader in China · Expert in Trace Element Testing
NMPA, CE
Background
The clinical impact of toxic elements on human health has received growing attention in recent years. Increasing studies and guidelines now highlight the importance of lead and cadmium testing in clinical practice. In 2012, the American College of Obstetricians and Gynecologists (ACOG) issued Committee Opinion No. 533, later reaffirmed in 2018, recommending that lead exposure risk assessment should be conducted during the first clinical encounter with pregnant or breastfeeding women, as part of a comprehensive health risk evaluation. In China, the Ministry of Health issued a 1999 directive titled "Notice on Improving the Quality of the Birth Population", which called on healthcare institutions at all levels to gradually include maternal and neonatal blood lead testing as a routine clinical examination during the perinatal period.
This product utilizes atomic absorption spectrometry (AAS) and requires only a minimal sample, no complex pretreatment, and can deliver quantitative results for lead and cadmium in as fast as 1.5 minutes.
An optional automated sampler is available to further improve efficiency and ease of use.
Sample types: Whole blood, urine, breast milk
Detection range: Quantitative measurement of lead and cadmium concentrations
The product has been designated for 18 consecutive years as the official testing equipment for blood lead analysis in the "Urban Children's Lead Exposure Monitoring and Comprehensive Intervention Program", jointly conducted by the Capital Institute of Pediatrics and the WHO Collaborating Center for Children's Health.
